Genome-Wide Assessment of the Binding Effects of Artificial Transcriptional Activators by High-Throughput Sequencing by Chandran, Anandhakumar et al.
Title Genome-Wide Assessment of the Binding Effects of ArtificialTranscriptional Activators by High-Throughput Sequencing
Author(s)Chandran, Anandhakumar; Syed, Junetha; Li, Yue; Sato,Shinsuke; Bando, Toshikazu; Sugiyama, Hiroshi




This is the accepted version of the following article:
[Anandhakumar Chandran, Junetha Syed, Yue Li, Shinsuke
Sato, Toshikazu Bando, Hiroshi Sugiyama. Genome‐Wide
Assessment of the Binding Effects of Artificial Transcriptional
Activators by High‐Throughput Sequencing. ChemBioChem
(2016), 17, 20, 1905-1910], which has been published in final
form at https://doi.org/10.1002/cbic.201600274. This article
may be used for non-commercial purposes in accordance with
Wiley Terms and Conditions for Self-Archiving.; The full-text
file will be made open to the public on 19 October 2017 in
accordance with publisher's 'Terms and Conditions for Self-
Archiving'.; This is not the published version. Please cite only





FULL PAPER    





Genome-Wide Assessment of the Binding Effects of Artificial 
Transcriptional Activators by Utilizing the Power of High-
Throughput Sequencing 
Anandhakumar Chandran,[a] Junetha Syed,[a] Yue Li,[a] Shinsuke Sato,[b] Toshikazu Bando,[a] Hiroshi 
Sugiyama,*[a,b] 
Abstract: One of the major goals in DNA-based personalized 
medicine is the development of sequence-specific small molecules 
to target the genome by means of synthetic biology; SAHA-PIPs 
belong to such class of small molecules. In a complex eukaryotic 
genome, the differential biological effects of SAHA-PIPs remain 
unclear. These questions can be addressed by directly identifying 
the binding regions of small molecules across the genome; however, 
it is a challenge to enrich specifically the small-molecule-bound DNA 
without chemical cross-linking. Here, we developed a method using 
high-throughput sequencing to map the binding area of non-cross-
linked small molecules throughout the chromatinized human genome. 
Analysis of the sequenced data confirmed the presence of specific 
binding sites for SAHA-PIPs among the enriched sequence reads. 
Mapping the binding sites and enriched regions on the human 
genome clarifies the origin of the distinctive biological effects of 
SAHA-PIP. This approach will be useful for identifying the 
functionality of other small molecules on a large scale. 
Introduction 
The competency of each cell type to maintain its precise 
biological characteristics depends on the inherited differences in 
chromatin packaging named as nucleosomes. These preset 
arrangements in the genome enable the epigenome to control 
the fate of the cell by regulating a specific set of genes.[1,2] 
Notably, changes in the epigenetic machinery can lead to cell 
plasticity, which triggers cellular reprogramming.[3] Although 
various histone marks are considered to be the gears of the 
epigenome, methylation and acetylation are the extensively 
studied histone modifications in governing chromatin 
dynamics.[4] Epigenetic alterations by these chromatin-modifying 
enzymes result in the alteration of gene expression. Given that 
most epigenetic marks are dynamic, some of these post 
translational histone modifications are reversible by enzymes. [5] 
Synthetic biology approaches aim at controlling these 
modifications by using sequence-specific artificial small 
molecules and is one of the key objectives in developing 
personalized nucleic acid targeted therapy. 
The use of the versatile N-methylpyrrole (P) N-
methylimidazole (I) synthetic polyamides (PIPs) in regulating 
sequence specific gene expression has been successful and 
these molecules are efficient enough to penetrate cell 
membranes even at nanomolar concentrations. PIPs belong to 
the category of DNA minor-groove binders that can recognize 
each of the Watson–Crick base pairs with a programmable 
canonical DNA binding rule. The predetermined DNA binding 
rule of PIP is that an antiparallel arrangement of I opposite P (I–
P) recognizes a G–C base pair, P–I recognizes a C–G base pair, 
and P–P recognizes either T–A or A–T base pairs.[6,7] 
Previously, we have reported the design and application of 
SAHA-PIPs as epigenetically active artificial transcriptional 
regulators. SAHA-PIP was synthesized by conjugating a histone 
deacetylase inhibitor SAHA (suberoyl anilide hydroxamic acid) 
with PIPs. These studies showed that SAHA-PIPs can 
specifically trigger efficient transcriptional activation of an 
epigenetically silent gene network in human dermal fibroblasts.[8] 
However, the actual binding sites of SAHA-PIPs in a broad 
context were unclear. Therefore, previously we used Bind-n-Seq 
methods to understand the sequence recognition property of the 
SAHA-PIPs. [9] Our investigation on the global gene expression 
of a chemical library containing 32 SAHA-PIPs in human dermal 
fibroblast cells showed that each of the conjugates can regulate 
a unique gene set, including some therapeutically important 
genes. [10] The underlying factors and characteristics of SAHA-
PIPs that lead to regulation of a unique gene set remain 
unresolved. Previous studies with alkylating PIP suggested that 
the genomic regions occupied by histones can influence the 
binding and gene regulating effect of PIPs. [11] 
Beforehand, “Cross-linking of small molecules for isolation of 
chromatin” (COSMIC) was used to determine the high-affinity 
binding of PIP in the nucleus by conjugating a photo-cross-linker 
with PIP.[12] Our recent report on the use of alkylating-PIP was 
further extended to examine the binding conformation.[13] These 
studies established a platform upon which to investigate the PIP 
conjugate binding mechanism in chromatinized human genome. 
It remained an unresolved challenge to understand the binding 
behavior of SAHA-PIPs without any covalent cross-linking to 
DNA. In this report, we have developed a method to understand 
the binding behavior of SAHA-PIPs by combining micrococcal 
nuclease (MNase) digestion, affinity purification, and high-
throughput sequencing. Our recent studies showed that SAHA-
PIP I (Scheme 1) could precisely trigger the expression of 
essential pluripotency genes such as OCT-3/4, NANOG, and 
DPPA4, on the otherhand its structural counterpart, SAHA-PIP K 
(Scheme 1), activated a completely different set of genes related 
to germ-cell such as PIWIL2, PIWIL4, and MOV10L1 in human 
dermal fibroblast cells.[14,15] These observations prompted us to 
study the genomic occupancy of SAHA-PIPs I and K on the 
chromatinized human genome. The results of this study reveal 
the high-affinity binding sites and binding preferences of SAHA-
PIPs across the complex human genome. 
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Scheme 1. a) Structure of SAHA-PIP I and SAHA-PIP K. b) SAHA-PIP I and 
SAHA-PIP K binding sequences based on PIP-DNA binding rule. 
Results and Discussion 
As an artificial transcription activators, the biological effects of 
SAHA-PIP I and K mainly rely on their high-affinity binding 
preferences in the chromatinized genome. To characterize this 
phenomenon, we used our recent report[13] as a platform and 
developed a method shown in Figure 1, with non-covalently 
binding small molecules in the extracted nucleus of live cells. 
 
                
                                Scheme 2. Chemical structures of 3 and 4 
 
For this study, we used SAHA-PIP I (SAHA-β-β-Py-Im-Im-Py-γ-
Py-Py-Py-Py-β-(+)PEG12-Biotin; 3) and SAHA-PIP K (SAHA-β-
β-Im-Im-Py-Py-γ-Py-Py-Py-Py-β-(+)PEG12-Biotin; 4), from our 
previously reported library of biotin-conjugated SAHA-PIPs[9] 
(Scheme 2). The compounds were synthesized as described in 
the previous report (see the Supporting Information). Our results 
unambiguously showed that neither the modification in the 
SAHA moiety nor attachment of biotin in SAHA-PIPs affected 
their binding specificity.[9] 
In breif, the nucleus was extracted from live human fibroblast 
BJ cells (neonatal foreskin (ATCC, USA)) and incubated with 3 
and 4 (400 nM) separately, control experiments were performed 
without SAHA-PIPs. To avoid the dissociation of non-covalently 
bound 3 and 4, and to obtain the PIP bound target DNA 
fragment, MNase digestion was performed[16] (see the 
Supporting Information). After DNA fragmentation and nuclear 
protein digestion by proteinase K, PIP bound DNA was enriched 
and purified by using biotin-streptavidin chemistry based affinity 
purification. The extracted genomic DNA from the biological 
triplicates were used to construct sequencing libraries and 
subjected to high-throughput sequencing, using standard 
sequencing methods for Ion PGMTM/ProtonTM 
High-quality sequencing reads were mapped with the human 
genome. To find the high-affinity binding sites of 3 and 4 over 
the control sequence reads (without any PIP treatment), 
uniquely mapped sequence data were randomly extracted by 
using subsampling Perl code and analyzed with a Bind-n-Seq 
pipeline and motif calling.[17] The identified high-affinity binding 
motifs for 3 and 4 are shown in Figure 2 and the sequence 
details are in Table S1-S6.   One of the highly enriched motifs 
shown in figure 2a for 3 obeyed well its canonical binding rule 
(5ʹ-WWCCWW-3ʹ), but the palindromic nature of the sequence 
could not allow the easy determination of its binding orientation.                               
Figure 1. MNase digestion and affinity purification-based high-throughput 
sequencing method pipeline using noncovalently binding PIP conjugates 
in the human nucleus from live cells. 
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 Figure 2b shows the high affinity binding sites of PIP 
conjugate 4 with significant enrichment scores; the obtained 
data revealed that 4 can bind to DNA in both the forward (N-
terminal to C-terminal of PIP recognize 5ʹ to 3ʹ of DNA) and 
reverse orientation (N-terminal to C-terminal of PIP recognize 3ʹ 
to 5ʹ of DNA) with an enrichment ratio of 13.91 and 14.63, 
respectively. This type of binding was also observed in our 
previous report.[9] Comparative assessments of SAHA-PIPs 
binding on chromatinized genomic DNA with a protein-free 
synthetic DNA library[9] showed that both experimentally derived 
high-affinity binding motifs follow the PIP binding rule. Although 
the side-by-side arrangement of P–I/I–P in PIP recognizes a 
unique base pair (CG/GC), the P–P arrangement shows a slight 
variation in recognizing A/T (W). This variation may be due to 
the primary and secondary preferential nucleotide distribution in 
the given sequence context. Interestingly their base 
recognition(W) strictly follows the canonical binding rule. 
                                                                                         
Revealing the unique gene set activation mechanism of PIP 
conjugates in the human genome: The epigenetically active 
form of 3 (SAHA-PIP I) (Scheme 1) was reported to activate an 
epigenetically silent pluripotency gene set in human fibroblast 
cells,[14] whereas its structural counterpart epigenetically 
active form of 4 (SAHA-PIP K) (Scheme 1) triggered the 
activation of meiosis controlling PIWI pathway genes in 
somatic cells, which is involved in germ-cell generation.[15] 
When the obtained 3 and 4 enriched sequence read signal 
and enrichment peaks (peaks were identified with respect 
to control data)[18] were mapped, the results were 
noteworthy. The data for PIP conjugate 3 showed 
enrichment peaks at the promoter regions of SAHA-PIP I 
upregulated genes associated with pluripotency: OCT3/4 
(also known as POU5F1: POU domain, class 5, 
transcription factor 1) (Figure 3a), DPPA4 (developmental 
pluripotency associated 4) (Figure S2a), and EPCAM 
(Figure S2b). In contrast, 4 did not show any significant level of 
enrichment at the SAHA-PIP I induced pluripotent genes. In line 
with this, enrichment peaks for 4 were observed in the promoter 
region and gene body of SAHA-PIP K upregulated genes 
involved in germ-cell generation such as PIWIL4, PIWIL2, and 
TDRD9 (Figure 3b, S2c and S2d respectively). Careful 
observation of TDRD9 shown in Figure S2d demonstrated the 
enrichment of peaks in the gene body but not around the 
promoter, explaining the reason behind the mild effect of SAHA-
PIP K on TDRD9 promoter acetylation, and the minor change in 
mRNA expression noted in our previous report.[15] Interestingly, 
compound 3 did not show any specific significant enrichment on 
either PIWIL4 or TDRD9; eventhough it displayed a mild 
enhancement on PIWIL2, but it could not be comparable with 
the effective significant enrichment by   conjugate 4. 
In contrast, neither 3 nor 4 showed any clearly enriched 
region on the housekeeping gene GAPDH (Figure S2e). 
Although the active forms of SAHA-PIP I and SAHA-PIP K have 
closely related recognition sites, their transcriptional activation 
network is distinctive to each other. Taken all together, our high-
throughput sequencing analysis of 3 and 4 enriched genomic 
regions in chromatinized human genome 
allowed us to provide; the direct evidence of 
DNA minor-groove binding SAHA-PIP’s 
differential gene activation mechanism in 
eukaryotic cells. 
Identification of the preferential 
binding region of PIP conjugates in the 
tightly packed heterochromatin region: 
As noted in the previous report, histone-
occupied chromatin regions play an 
important role in PIP binding preferences in 
genomic DNA.[11] To study the binding 
inclinations of SAHA-PIPs, we compared the 
genomic regions that were enriched with 3 
and 4 with the MNase-seq data of 
nucleosomal positioning from ENCODE at 
UCSC.[19,20] Heterochromatin play a critical 
role in gene silencing because of the tighter 
packaging of DNA.[21] 
Figure 3.  Identified genomic regions of PIP conjugates 3 and 4 binding and enrichment in a) 
OCT3/4 (POU5F1) b) PIWIL4.                                   
Figure 2. Identified high-affinity 
binding motif of a) 3 and b) 4 (forward 
and reverse binding) in the human 
genomic enriched sequence. 
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 Covalent modifications of eukaryotic histone tails such as 
histone methylation are vital for heterochromatin formation;[21,22] 
these modifications occur mainly through trimethylation at 
histone 3 lysine 9 (H3K9)[21,23] and lysine 27 (H3K27).[23,24] We 
therefore analyzed and compared the H3K9me3 and H3K27me3 
regions that were identified on the skin and lung fibroblast cell 
lines (NHEK (skin epidermal keratinocytes), NHDF-Ad (adult 
dermal fibroblasts skin), and NHLF (lung fibroblasts)),[20] along 
with the nucleosomal positioning data. 
Our comparative analysis showed that the 3 enriched 
genomic region with high-affinity binding site 
around the SAHA-PIP I upregulated NANOG[14] 
promoter is H3K27 trimethylated (Shown in Figure 
4a with blue shade) in the reported fibroblast cell 
lines and also falls under the nucleosomal region 
(MNase-seq data) (Figure 4a, last two tracks). 
Similarly, SAHA-PIP K highly upregulated 
MOV10L1[14] promoter region and gene body is 
enriched in 4, (also harboring its binding site) are 
trimethylated at both H3K9 and H3K27 (Figure 4b, 
blue shade) in the reported fibroblast cell lines; 
these regions are also packed into nucleosomal 
units (MNase-seq data) (Figure 4b, last two tracks). 
These results clearly demonstrate that both 3 
and 4 can also bind efficiently to the nucleosome 
within the possible heterochromatin-forming 
regions. This provides evidence on silent gene 
activation principle of SAHA-PIPs. 
Conclusions 
The application of high-throughput sequencing in 
chemical biology has produced some notable 
outcomes.[25] Furthermore, the identification of 
genomic targets by using small molecules help us 
in understanding the drug effects and optimise the 
drug design.[26] The combination of ChIP-seq and 
Chem-seq approaches[27,28] have been reported to 
characterise the protein-binding small molecules. 
Here, we report a method involving small 
molecules that form noncovalent interaction with 
DNA. We studied the high-affinity binding motif of 
such molecules and the corresponding enriched 
genomic regions. Annotation of 3 and 4 enriched 
region showed similar pattern of genomic region 
distribution (slightly varied in some genomic 
region) with high correlation among the 
experimentally identified peaks, actual binding 
sites and the deduced binding sites based on 
predetermined binding rule shown in Figure S3a 
and S3b. Comparative analysis of 3 and 4 
provided evidence for the differential activation of 
the gene network by epigenetically active forms 
such as SAHA-PIP I and SAHA-PIP K. These 
results also suggest a binding mechanism for 
SAHA-PIPs in actual chromatinized genome.  The 
following points can be noted in particular. i) Small 
variations in the P–I arrangement in PIP can result 
in a large difference in genome-wide binding site 
recognition. ii) The result that 3 and 4 bind on the 
nucleosomal region with histone marks may 
explain the epigenetic activation by SAHA-PIP of 
the silenced gene network. Given that this method 
 Figure 4. Binding and enrichment of PIP conjugates 3 and 4 in possible heterochromatin-
forming regions of a) NANOG promoter and b) MOV10L1 promoter. Possible heterochromatin 
regions were identified by mapping the MNase-Seq data of nucleosomal positioning with 
histone trimethylated regions of histone 3 lysine 9 and lysine 27. (Modified histone regions with 
PIP binding and enrichment site is shown in box.) 
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used non-cross-linking or noncovalent binding-based affinity 
purification, the approach is expected to be widely applicable to 
the study of genomic effects of other DNA-binding small 
molecules. 
Experimental Section 
See the Supporting Information for Synthesis, experimental protocols and 
data analysis  
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Evaluation of artificial 
transcriptional activating small 
molecules binding effects on 
human genome. Our previously 
reported SAHA PIPs library showed 
unique gene set activation. But its 
gene activation mechanism is 
uncertain with a complex human 
genome. Therefore, we developed 
high-throughput sequencing based 
method to address this query with a 
noncross-linking small molecule.  
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Synthesis of biotin-conjugated polyamides  
 
General scheme for Synthesis of biotin-conjugated  
 
 3 
Solvents and reagents were used as same as our previous report.[1] The EZ-Link 
NHS-PEG12-Biotin was purchased from Thermo Scientific (number 21312).The 
analytical HPLC was performed with a COSMOSIL 5C18-MS-II reversed phase 
column (4.6×150 mm, Nacalai) in 0.1% TFA in water with CH3CN as eluent at a flow 
rate of 1.0 mL/min, and a linear gradient elution of 0−100% CH3CN over 40 min with 
detection at 254 nm. The final products were analyzed by ESI-TOF-MS (Bruker).  
We followed the same synthetic root as our previous report. [1] PIP supported by oxime 
resin was prepared in a stepwise reaction by a reported Fmoc solid-phase procedure. 
The product with oxime resin was cleaved with 3,3'-Diamino-N-methyldipropylamine 
(500µL) at 55℃ for 3 hours. After filtration and evaporation, the resulted oil was 
quenched by Et2O. The obtained precipitation was washed with Et2O for three times and 
dried in vacuo. The product was used for the next coupling steps without further 
purification. 
A solution of polyamide (1eq), EZ-Link NHS-PEG12-Biotin (1.2eq) and DIEA (2eq) in 
DMF was stirred at room temperature for 1 hour. After consumption of starting material 
was confirmed by HPLC, Et2O was added to the mixture and the resultant was collected 
by centrifugation, and washed by Et2O and CH2Cl2. The crude product was purified by 
reverse-phase HPLC. After lyophilization the final product was obtained. 
SAHA-β-β-Py-Im-Im-Py-γ-Py-Py-Py-Py-β-(+)-PEG12-Biotin (3) 
Analytical HPLC: tR= 17.2 min (0.1% TFA-CH3CN, 0−100%, 40min). ESI-TOF-MS 
m/z: calcd for C119H173N29O31S [M+2H]2+ 2538.2573, found 2538.0851. 
SAHA-β-β-Im-Im-Py-Py-γ-Py-Py-Py-Py-β-(+)-PEG12-Biotin (4) 
Analytical HPLC: tR= 17.3 min (0.1% TFA-CH3CN, 0−100%, 40min). ESI-TOF-MS 
m/z: calcd for C119H173N29O31S [M+2H]2+ 2538.2573, found 2538.2536. 
 4 
Compound 3 and 4 binding site and binding region identification in human 
genome (Mainly we have followed our recent report)[2] 
Nucleus extraction and PIP conjugate incubation: 
       75% -80% confluent human fibroblast BJ cells (neonatal foreskin (ATCC, USA)) 
were used to extract nuclei.[3] In brief, P6 of BJ-HFF cells were grown in Dulbecco's 
modified eagle medium (DMEM, Nacalai Tesque, Japan) supplemented with 10% FBS 
(FBS, Japan Serum) in a humidified atmosphere of 5% CO2 at 370C. At 75%-80% 
confluency, the cells were isolated by PBS washing followed by 3-4 minutes 
tripsinization.  Isolated 2x106 cells were washed twice with ice cold PBS. The cell 
membrane was digested with 5ml of ice cold NP-40 lysis buffer (10 mM Tris-HCl (pH 
7.4), 10 mM NaCl, 3 mM MgCl2, 0.5% Nonidet P-40, 0.15 mM spermine, 0.5 mM 
spermidine and 0.1x protease inhibitor cocktail) for 5 minutes on ice. Loosen pellet of 
cell nuclei were obtained by centrifugation and dissolved in binding and resuspension 
buffer (10 mM Tris-Cl (pH 8.0), 5 mM MgCl2, 1 mM DTT, 0.3 M KCl, 0.3x protease 
inhibitor cocktail and 10% glycerol). 3 and 4 were dissolved in DMSO and incubated 
(400nM of 3 and 4, 0.1% final concentration of DMSO) separately with the isolated 
nuclei about 16-18 hrs at 4°C. For the control experiments only DMSO (PIPs were 
dissolved in DMSO) was used without PIP conjugates. Concentrations were used 
according to the previous reports.[2,4,5]  
MNase digestion: 
After PIP derivatives incubation, micrococcal nuclease (MNase) buffer[3] (10 mM 
Tris-HCl (pH 7.4), 15 mM NaCl, 60 mM KCl, 0.15 mM spermine, 0.5 mM spermidine 
and 0.1x protease inhibitor cocktail) pre-washed nuclei was subjected to MNase (Takara, 
Japan) digestion at 37oC for 30 min. Sonication shearing may affect the non-covalently 
 5 
bound PIP, so we used MNase digestion. To avoid protein hindrance during affinity 
purification, the MNase digested nucleosomes were treated with proteinase K.  
Affinity purification 
Protein digested PIP bound DNA containing suspension was mixed with mixed with 
modified COSMIC buffer[4] (20 mM Tris-Cl (pH 8.1), 2 mM EDTA, 150 mM NaCl, 
0.1x protease inhibitor cocktail , 1% Triton-X100, and 0.1% SDS). 10% of the sample 
was saved as input DNA. Dynabeads MyOne C1 preparation: Streptavidin-coated 
magnetic beads (Dynabeads MyOne C1, Life Technologies, USA) was washed twice 
with modified COSMIC buffer after removing the suspension solution. 0.5mg per 
sample of beads was incubated with samples at 4oC for 16 hrs by way of rotor mixing. 
After incubation, samples were subjected to sequential of washing with buffer 1, 
washing Buffer 2 (10 mM Tris-Cl (pH 8.0), 250 mM LiCl, 1 mM EDTA, 0.5% NP40), 
washing Buffer 3 (10 mM Tris-Cl (pH 7.5), 1 mM EDTA, 0.1% NP-40), and finally 
with TE. Washed samples were resuspended in elution buffer-I	(10 mM Tris-HCl (pH 
7.6), 0.4 mM EDTA and 100 mM KOH) and DNA was eluted by heating at 90°C for 30 
min. The unrecovered DNA with the beads were subjected to second elution using 
elution buffer-II (2% SDS, 100mM NaHCO3 and 3mM biotin) with the heating of 65°C 
for 8-12 hours. The eluted DNA samples were purified with the QIAquick PCR 
purification Kit (Qiagen, CA, USA) and quantified using Nanodrop (Figure S1). The 
quantification of purified DNA samples confirmed the pull-down efficiency of 3 and 4 
with respect to the biological triplicates (Figure S1). 
 
High-throughput sequencing library construction and sequencing 
Optimum amount of purified DNA was pooled (To get sufficient amount of DNA) from 
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the biological triplicates and sequencing libraries were prepared by using Ion XpressTM 
Plus gDNA Fragment Library preparation reagents and protocols (Life techologies, 
USA) as per the instruction. Adapter ligated DNA was amplified and purified. The 
purified libraries were analyzed with Agilent DNA High sensitivity BioAnalyzer kit 
(Agilent technologies, USA). The sequencing was carried out, as 1) template 
preparation using Ion PGMTM template OT2 200 v2 kit and Ion PITM template OT2 200 
kit in Ion one touch2 system. 2) The templates enrichment on Ion one touch ES. 3) 
Sequencing the enriched libraries with Ion PGMTM/ Ion ProtonTM sequencer using Ion 
PGMTM sequencing 200 kit v2 / Ion PITM Sequencing 200 kit v3 and 318 v2 chip/ Ion PI 
chip according to the manufacturer’s guidelines. Single read sequencing was performed 
with 260-300 flow, 28-31 million post filtered reads per library was produced. Ion 
torrent suit was used for the preliminary data analysis. TMAP 4.4.2 was used for 
aligning the good quality reads with human genome, To identify high-affinity binding 
motif a random selected 10-15% of uniquely mapped reads were used (Normalization 
performed with control data). We followed our previous analysis pipeline for motif 
calling.[1, 2, 6] The aligned data was further analysed for enriched peak calling using 
standard ChIP-seq analysis program MACS 1.4.2.[7] (SAHA PIP enriched reads as a 
treat and control (without SAHA-PIP) reads as control) MACS enriched signals and 
peak regions were visualized on UCSC genome browser to identify uniquely enriched 
regions between 3 and 4.[8]  To analyse the influence of chromatin bound DNA on PIP 
conjugates binding, we compared various histone marks and nucleosomal positioning 



















Figure S2.  Identified genomic regions of PIP conjugates 3 and 4 binding and enrichment in a) 












Figure S3. Comparison of genomic binding and enriched region with binding rule based 
binding site. a) For compound 3. b) For compound 4. 
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Table S1: Base composition for 3 enriched high-affinity binding motif (Figure 2a) 
Base/Position	 1	 2	 3	 4	 5	 6	
A	 101542	 74463	 95607	 121875	 1795588	 135205	
C	 133568	 0	 1660957	 1729644	 0	 128146	
G	 82898	 0	 110992	 80128	 44857	 0	
T	 1723257	 1966802	 173709	 109618	 200820	 1777914	
 
 
Table S2: Base composition in percentage (%) for 3 enriched high-affinity binding 
motif (Figure 2a) 
Base/Position	 1	 2	 3	 4	 5	 6	
A	 4.97	 3.64	 4.68	 5.97	 87.96	 6.62	
C	 6.54	 0	 81.37	 84.73	 0	 6.27	
G	 4.06	 0	 5.43	 3.92	 2.19	 0	
T	 84.42	 96.35	 8.50	 5.37	 9.84	 87.10	
 
 
Table S3: Base composition for 4 enriched high-affinity forward binding motif (Figure 
2b) 
Base/Position	 1	 2	 3	 4	 5	 6	
A	 11484904	 377658	 154445	 0	 596910	 11407282	
C	 0	 449598	 0	 11554127	 10168801	 222343	
G	 330252	 400567	 0	 476424	 1186363	 325987	
T	 619941	 11207274	 12280652	 404546	 483023	 479485	
 
 
Table S4: Base composition in percentage (%) for 4 enriched high-affinity forward 
binding motif (Figure 2b) 
Base/Position	 1	 2	 3	 4	 5	 6	
A	 92.36	 3.037	 1.24	 0	 4.80	 91.73	
C	 0	 3.61	 0	 92.92	 81.78	 1.78	
G	 2.65	 3.22	 0	 3.83	 9.54	 2.62	





Table S5: Base composition for 4 enriched high-affinity reverse binding motif (Figure 
2b) 
Base/Position	 1	 2	 3	 4	 5	 6	
A	 10409874	 9781071	 646082	 392937	 521859	 10299390	
C	 0	 0	 340220	 659086	 435721	 0	
G	 0	 481514	 0	 9062792	 9343911	 0	
T	 148100	 295389	 9571672	 443159	 256483	 258584	
 
 
Table S6: Base composition in percentage (%) for 4 enriched high-affinity reverse 
binding motif (Figure 2b) 
Base/Position	 1	 2	 3	 4	 5	 6	
A	 98.60	 92.64	 6.11	 3.72	 4.94	 97.55	
C	 0	 0	 3.22	 6.24	 4.13	 0	
G	 0	 4.56	 0	 85.84	 88.50	 0	
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